156 related articles for article (PubMed ID: 18180227)
1. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations.
Lim HS; Yoon W; Chung TW; Kim JK; Park JG; Kang HK; Bom HS; Yoon JH
Radiographics; 2007 Oct; 27 Suppl 1():S197-213. PubMed ID: 18180227
[TBL] [Abstract][Full Text] [Related]
2. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
3. FDG PET, PET/CT, and breast cancer imaging.
Rosen EL; Eubank WB; Mankoff DA
Radiographics; 2007 Oct; 27 Suppl 1():S215-29. PubMed ID: 18180228
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose-PET in the management of breast cancer.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
7. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application.
Chakraborty D; Basu S; Ulaner GA; Alavi A; Kumar R
PET Clin; 2018 Jul; 13(3):355-361. PubMed ID: 30100075
[TBL] [Abstract][Full Text] [Related]
9. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
10. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.
Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S
Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581
[TBL] [Abstract][Full Text] [Related]
11. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
13. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
14. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
15. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary.
Freudenberg LS; Fischer M; Antoch G; Jentzen W; Gutzeit A; Rosenbaum SJ; Bockisch A; Egelhof T
Med Princ Pract; 2005; 14(3):155-60. PubMed ID: 15863988
[TBL] [Abstract][Full Text] [Related]
16. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
Landheer ML; Steffens MG; Klinkenbijl JH; Westenberg AH; Oyen WJ
Br J Surg; 2005 Nov; 92(11):1363-7. PubMed ID: 16187254
[TBL] [Abstract][Full Text] [Related]
17. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
Kitajima K; Miyoshi Y
Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
[TBL] [Abstract][Full Text] [Related]
18. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
19. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
[TBL] [Abstract][Full Text] [Related]
20. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]